Depressive Disorders - Baltics | Statista Market Forecast

Revenue in the Depressive Disorders market is projected to reach US$26.01m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 1.81%, resulting in a market volume of US$28.46m by 2029.
In global comparison, most revenue will be generated United States (US$6.26bn in 2024).
In relation to total population figures, per person revenues of US$82.38 are generated in 2024.

Depressive disorders are a common type of mental illness. Symptoms include depressive moods such as feeling sad, low concentration, low self-worth, loss of interest in activities, and, in some cases, thoughts of suicide. Common treatments for depressive disorders include psychological treatments such as psychotherapy, behavioral therapy, and antidepressant medication.

The Depressive Disorders market in the Mental Health market represents the market for antidepressant drug sales. Different types of antidepressants are usually prescribed for the treatment of mild to serious cases of depression, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor (SNRIs), serotonin modulators, as well as tricyclic and tetracyclic antidepressants.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Novartis AG, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Patheon Inc, and Sandoz Inc.

Antidepressant drugs
Selective serotonin reuptake inhibitors (SSRIs)
Serotonin norepinephrine reuptake inhibitor (SNRIs)
Serotonin modulators
Tricyclic and tetracyclic antidepressants

Psychotherapy
Mood stabilizers
Anti-anxiety and stimulant medications
Behavioral therapy

The Depressive Disorders market in Baltics is experiencing significant growth and development, driven by several key factors.

Customer preferences: In line with global trends, customers in the Baltics are increasingly seeking effective treatments for depressive disorders. They are becoming more aware of mental health issues and the importance of seeking professional help. As a result, there is a growing demand for pharmaceutical products and therapy services that can effectively treat and manage depressive disorders.

Trends in the market: One major trend in the Depressive Disorders market in Baltics is the increasing adoption of antidepressant medications. Pharmaceutical companies are introducing new and improved antidepressant drugs that offer better efficacy and fewer side effects. These medications are gaining popularity among healthcare professionals and patients alike, leading to a rise in their consumption.Another trend in the market is the growing popularity of psychotherapy as a treatment option for depressive disorders. Patients are increasingly seeking therapy services from qualified professionals who can provide counseling and support. This trend is driven by the recognition that therapy can be an effective alternative or complement to medication in managing depressive disorders.

Local special circumstances: The Baltics, comprising Estonia, Latvia, and Lithuania, have a unique set of circumstances that contribute to the development of the Depressive Disorders market. These countries have experienced significant social and economic changes in recent years, including the transition from a planned to a market economy. These changes have led to increased stress and anxiety among the population, which in turn has contributed to the rising prevalence of depressive disorders.

Underlying macroeconomic factors: The economic growth and development in the Baltics have played a significant role in shaping the Depressive Disorders market. As the economies of these countries continue to grow, there is an increase in disposable income and healthcare spending. This allows individuals to afford better healthcare services and medications, including those for depressive disorders.Furthermore, the government's focus on improving healthcare infrastructure and services has also contributed to the growth of the Depressive Disorders market. Increased investment in healthcare facilities, training of healthcare professionals, and public awareness campaigns have all contributed to the improved diagnosis and treatment of depressive disorders.In conclusion, the Depressive Disorders market in Baltics is experiencing growth and development due to customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The increasing awareness of mental health issues, the availability of improved medications and therapy services, and the economic growth in the region are all contributing to the expansion of the market.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.